Streetwise Reports' Article Archives — October 2022 back to current month (18)
This developer of cancer immunotherapies will take possession of these clinical-stage assets in a transaction with GSK and subsequently advance them toward approval, noted a ROTH Capital Partners report.
Biotech Co. Achieves High ORRs in Ph. 1 NSCLC Trial (10/28/2022)
Shares of Nuvalent Inc. traded 60% higher to a new 52-week intraday high after the company reported initial data from its Phase 1 ARROS-1 trial of NVL-520 demonstrating positive objective response rates in patients with ROS1-Positive non-small cell lung cancer.
Potential ROI With German Biopharma Co. Notable (10/27/2022)
This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report.
Shares of full-service clinical contract research organization Medpace Holdings Inc. traded 37% higher yesterday after the company reported Q3/22 financial results that included a nearly 30% YoY increase in revenue.
Vaccine Co. Posts Positive Ph. 1/2 IPD Trial Results (10/25/2022)
Shares of Vaxcyte Inc. traded 61% higher yesterday to a new 52-week high after the company reported positive topline results from its Phase 1/2 study of VAX-24, its novel 24-valent pneumococcal conjugate vaccine candidate being developed to prevent invasive pneumococcal disease in adults 18 to 64 years of age.
Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy its stock.
Biopharma Co. Shows Large Potential Return (10/21/2022)
Palatin Technologies Inc.'s third-party clinical trial of Vyleesi in women with hypoactive sexual desire disorder was just published in the Journal of Clinical Investigation, and the biopharma offers investors significant potential return, noted an H.C. Wainwright & Co. report.
Shares of Intuitive Surgical Inc. traded 9% higher yesterday after the robotic surgical device maker reported Q3/22 earnings that included an 11% YoY increase in revenue and a 13% YoY increase in its installed da Vinci Surgical System base.
Industrial hemp is legal in all 50 states, and companies are working to get CBD, insulation, textiles, and biofuel made from it to the masses. These three companies hope their partnership will help connect the growers and buyers.
Biotech Co.'s Target Price Over Three Times Current (10/13/2022)
Expanded interim data from the Phase 2 trial of this biotech's lead asset PDS0101 in HPV16-associated cancers are consistent with previously reported results from the same study. Read more to discover why H.C Wainright & Co. believes this stock is a Buy with a target price over three times the current.
With this and other clinical studies, the U.S. company has a busy and, thus, catalyst-rich Q4/22 ahead, noted an H.C. Wainwright & Co. report.
Shares of DICE Therapeutics Inc. traded 62% higher yesterday and established a new 52-week intraday high after the company reported positive topline data from its Phase 1 DC-806 Psoriasis study.
Chen Reveals His Picks for Last Quarter (10/11/2022)
Asset manager Chen Lin's picks for the home stretch of 2022 include several biotechs and some precious metals companies.
Provention Bio Inc.'s shares traded 25% higher yesterday after the company reported it is joining forces with Sanofi U.S. to support the potential upcoming U.S. launch of its teplizumab for use in delaying the onset of clinical type 1 diabetes in at-risk patients. The U.S. FDA is expected to rule on the firm's Biologics License Application in mid-November 2022.
Biopharma Target Price 10 Times Current (10/06/2022)
Read to learn why ROTH Capital Partners gave Atai Life Sciences NV a Buy rating and a target price 10 times its current.
Biotech Co.'s Drug Showing 'Early Signs of Benefit' (10/06/2022)
With this upcoming analysis, the board will determine whether the Phase 2b/3 trial may continue to completion, noted a ROTH Capital Partners report.
The data suggest this treatment could be safer and more effective in treating proliferative vitreoretinopathy than compounded methotrexate, noted a Laidlaw & Co. report.
Co. Uses RNA Editing as Treatment for Rare Disease (10/03/2022)
The firm plans to advance its alpha-1 antitrypsin deficiency program into the clinic next year, noted an H.C. Wainwright & Co. report.
|"We expect PMN to commence formal Phase 1 testing later this year."|